• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of adjuvant-combined nasal influenza vaccine

Research Project

Project/Area Number 04557026
Research Category

Grant-in-Aid for Developmental Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field Virology
Research InstitutionNational Institute of Health, Dept.of Pathology

Principal Investigator

TAMURA Shinichi  N.I.H Chief, 感染病理部, 室長 (20100084)

Co-Investigator(Kenkyū-buntansha) OGAWA Kouji  kitasato Inst., 耳鼻咽喉科, 部長 (20160765)
KAMIYA Hitoshi  Mie Hosp., 三重病院・小児感染症, 院長 (20024656)
AIZAWA Chikara  Kitasato Inst., 技術部, 部長 (80072362)
KOJIMA Asato  N.I.H, 感染病理部, 室長 (30100077)
KURATA Takeshi  N.I.H, 感染病理部, 部長 (50012779)
Project Period (FY) 1992 – 1994
Project Status Completed (Fiscal Year 1994)
Budget Amount *help
¥19,700,000 (Direct Cost: ¥19,700,000)
Fiscal Year 1994: ¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 1993: ¥5,500,000 (Direct Cost: ¥5,500,000)
Fiscal Year 1992: ¥11,300,000 (Direct Cost: ¥11,300,000)
Keywordsinfluenza / intranasal vaccination / inactivated vaccine / adjuvant / heat-labile toxin / IgA / 交差感染阻止
Research Abstract

Natural influenza virus has been shown to be superior to the inactivated vaccine for inducing cross-protection against variants within a subtype of A type virus. The cross-protection induced by natural infection seems to be largely due to the induction of cross-reacting IgA antibodies in the respiratory tract. These facts suggest that the development of immunization procedure to stimulate mucosal IgA antibody production would improve the protective efficacy of the current inactivated vaccine. In this regard, intranasal immunization of inactivated vaccine has been advocated as means of inducing secretory IgA and systemic IgG antibodies against influenza. However, the intranasal immunization of inactivated vaccine alone cannot easily generate the secretory IgA antibodies. Under these circumstances, we attempted to inoculate intranasally the current inactivated vaccine together with a potent adjuvant, cholera toxin B subunit (CTB) containing 0.1% of CT,in mice. The results demonstrated that the nasal administration of the adjuvant-combined vaccine into mice can mimic the efficacy of live virus in inducing cross-protection against variant virus challenge. Moreover, we examined the effect of the intranasal immunization of the adjuvant-combined vaccine on IgA and HI antibody responses in humans. The results demonstrated that the adjuvant-combined vaccine can elicit significantly not only secretory IgA antibody but also serum HI antibody, as compared with vaccine alone, in humans.

Report

(4 results)
  • 1994 Annual Research Report   Final Research Report Summary
  • 1993 Annual Research Report
  • 1992 Annual Research Report
  • Research Products

    (19 results)

All Other

All Publications (19 results)

  • [Publications] Tamura, S. -I. et al.: "Superior cross-protective effect nasal vaccination to subcutaneous inoculation with influenza HA vaccine." Eur. J. Immunol.22. 477-481 (1992)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura, S. -I. et al.: "Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit." J. Immunol.149. 981-988 (1992)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura, S. -I. et al.: "Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice." Vaccine. 12. 310-316 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura, S. -I. et al.: "Synergistic action of cholera toxin B subunit( and E. coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine" Vaccine. 12. 419-426 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura, S. -I. et al.: "Esherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine." Vaccine. 12. 1083-1089 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura, S. -I. et al.: "Effect of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin." Vaccine. 13. 1238-1240 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1994 Final Research Report Summary
  • [Publications] Tamura,S.‐I.et al.: "Formulation of inactivated influenza vaccines for providing effective cross‐protection by intranasal vaccination in mice." Vaccine. 12. 310-316 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tamura,S.‐I.et al.: "Synergistic action of cholera toxin B subunit(and E.coli heat‐labile toxin B subunit)and a trace amount of cholera...." Vaccine. 12. 419-426 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tamura,S.‐I.et al.: "E.coli heat‐labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influ...." Vaccine. 12. 1083-1089 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tamura,S.‐I.et al.: "Effect of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin." Vaccine. 12. 1234-1240 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tamura,S.‐I.et al.: "Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of...." Vaccine. (in press). (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Asanuma,H.et al.: "Cross‐protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration." Vaccine. (in press). (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tamura,S.-I.,et al.: "Formulation of inactivated influenza vaccines for providing effectivecross-protection by intranasal vaccination in mice." Vaccine. (in press). (1993)

    • Related Report
      1993 Annual Research Report
  • [Publications] Tamura,S.-I.,et al.: "Synergistic action of cholera toxin B subunit (and Esherichia coli heat-labile toxin B subunit)and a trace amount of cholera whole toxin as an adjuvant" Vaccine. (in press). (1993)

    • Related Report
      1993 Annual Research Report
  • [Publications] Tamura,S.-I.,et al.: "Esherichia coli heat-labile enterotoxin B subunit supplemented with atrace amount of the holotoxin as an adjuvant for nasal influenza vaccine" Vaccine. (in press). (1994)

    • Related Report
      1993 Annual Research Report
  • [Publications] Tamura,S.-I.,et al.: "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine" Eur.J.Immunol.22. 477-481 (1992)

    • Related Report
      1992 Annual Research Report
  • [Publications] Hirabayashi,Y.,et al.: "Involvement of antigen-presenting cells in the enhance-ment of the in vitro antibody responses by cholera toxin B subunit" Immunology. 75. 493-498 (1992)

    • Related Report
      1992 Annual Research Report
  • [Publications] Gizurarson,S.,et al.: "Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit" Vaccine. 10. 101-106 (1992)

    • Related Report
      1992 Annual Research Report
  • [Publications] Tamura,S.-I.,et al.: "Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit" J.Immunol.149. 981-988 (1992)

    • Related Report
      1992 Annual Research Report

URL: 

Published: 1992-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi